Antiviral therapy for chronic hepatitis C in 2014

Area of Science:

• Hepatology
• Infectious Diseases
• Virology

Background:

• Hepatitis C Virus (HCV) infection remains a significant global health concern.
• Interferon-based therapies have been standard but are associated with significant side effects and longer treatment durations.
• The advent of direct-acting antivirals (DAAs) has revolutionized HCV treatment paradigms.

Purpose of the Study:

• To review landmark clinical trials of DAAs for HCV treatment.
• To evaluate the efficacy and tolerability of DAA-based regimens.
• To provide an expert commentary and future outlook on HCV management with DAAs.

Main Methods:

• Review of peer-reviewed landmark studies on direct-acting antivirals for HCV.
• Analysis of clinical trial data focusing on efficacy, safety, and treatment duration.
• Synthesis of findings to assess the impact of prior treatment history and cirrhosis.

Main Results:

• All-oral DAA therapies are now available for common HCV genotypes.
• DAA treatment is generally well-tolerated with few side effects and shorter durations.
• Prior treatment history or presence of cirrhosis does not significantly impact eradication rates with DAAs.

Conclusions:

• DAAs represent a major advancement in HCV management, offering highly effective and tolerable treatment options.
• The efficacy of DAAs is consistent across patient populations, including those with prior treatment or cirrhosis.
• Future HCV management will likely be dominated by DAA-based all-oral regimens.